Tarsus Pharmaceuticals, Inc. TARS Business Segments — Other reconciling items
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SegmentReportingOtherItemAmount.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s business segments — other reconciling items.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s business segments — other reconciling items?
- Tarsus Pharmaceuticals, Inc. (TARS) reported business segments — other reconciling items of -$845K in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s business segments — other reconciling items changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s business segments — other reconciling items decreased by 172.8% year-over-year, from $1.16M to -$845K.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s business segments — other reconciling items?
- Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s business segments — other reconciling items has grown at a 99.7% compound annual growth rate (CAGR), from $621K to $4.95M.
- What does business segments — other reconciling items mean?
- Includes non-recurring or peripheral financial adjustments that are not directly attributable to the core operating activities of the business segment. These items are necessary to reconcile segment performance with the overall consolidated financial statements.